RMD

$225.99-1.42 (-0.62%)

Market ClosedAs of Mar 20, 8:00 PM UTC

ResMed Inc.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPROTranscriptsPROStatementsPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$225.99
Potential Upside
0.3%
Whystock Fair Value$226.56
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Instruments & Supplies

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sl...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$32.99B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
22.38
Beta
Defensive asset. Lower volatility than the S&P 500.
0.89
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Elite ROE. Management converts capital into profit efficiently.
22.16%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
2.32

Recent News

Zacks
Mar 19, 2026

After Plunging 12.0% in 4 Weeks, Here's Why the Trend Might Reverse for ResMed (RMD)

ResMed (RMD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 17, 2026

ResMed (RMD) Upgraded to Buy: Here's What You Should Know

ResMed (RMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 17, 2026

Is Resmed Stock the Right Pick for Your Portfolio Now?

RMD expands mask and device sales while maintaining strong liquidity, but macro and competitive pressures loom.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Zacks
Mar 17, 2026

After Plunging 8.7% in 4 Weeks, Here's Why the Trend Might Reverse for ResMed (RMD)

The heavy selling pressure might have exhausted for ResMed (RMD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 14, 2026

Is It Time To Reconsider ResMed (RMD) After The Recent Share Price Pullback

If you are wondering whether ResMed's current share price still reflects good value or if most of the upside is already priced in, you are in the right place. ResMed shares last closed at US$230.84, with returns of 3.9% over 1 year, 14.7% over 3 years, 29.9% over 5 years, and more recent moves of an 8.7% decline over 7 days and an 11.1% decline over 30 days that may be changing how the market views its risk and return trade off. Recent coverage of ResMed has focused on the company as a major...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.